Arcutis Biotherapeutics ARQT
NASDAQ ARQT
$23.90 +0.24 (+1.01%)
As of: Sep 4, 2026 · 3:59 PM EDT

Arcutis Biotherapeutics (ARQT) Profit After Tax Growth (3y) (2022 - 2026)

Analysis

Arcutis Biotherapeutics (ARQT) Profit After Tax Growth (3y) (2022 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 6.30%
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 10.23%
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 91.31%
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 17.25%
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 37.89%
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 37.44%
8 Royalty Pharma 28.45 Bn 27.61 Bn - -38.56%
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 59.34%
10 Arcutis Biotherapeutics 3.12 Bn 2.88 Bn 118.92 Mn 30.28%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 30.28%
Mar 31, 2026 47.95%
Dec 31, 2025 30.91%
Sep 30, 2025 27.42%
Jun 30, 2025 38.23%
Mar 31, 2025 26.96%
Dec 31, 2024 46.76%
Sep 30, 2024 10.00%
Jun 30, 2024 -7.60%
Mar 31, 2024 0.61%
Dec 31, 2023 -24.86%
Sep 30, 2023 -5.42%
Jun 30, 2023 -26.09%
Mar 31, 2023 -41.94%
Dec 31, 2022 -78.52%
Sep 30, 2022 -95.41%
Jun 30, 2022 -101.09%
Mar 31, 2022 -112.98%